133 related articles for article (PubMed ID: 19963164)
1. Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study.
Safdar N; Smith J; Knasinski V; Sherkow C; Herrforth C; Knechtle S; Andes D
Diagn Microbiol Infect Dis; 2010 Jan; 66(1):7-15. PubMed ID: 19963164
[TBL] [Abstract][Full Text] [Related]
2. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody.
Peleg AY; Husain S; Kwak EJ; Silveira FP; Ndirangu M; Tran J; Shutt KA; Shapiro R; Thai N; Abu-Elmagd K; McCurry KR; Marcos A; Paterson DL
Clin Infect Dis; 2007 Jan; 44(2):204-12. PubMed ID: 17173218
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab induction in renal transplantation.
Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
[TBL] [Abstract][Full Text] [Related]
4. Steroid maintenance in repeat kidney transplantation: influence of induction agents on outcomes.
Sureshkumar KK; Hussain SM; Nashar K; Marcus RJ
Saudi J Kidney Dis Transpl; 2014 Jul; 25(4):741-9. PubMed ID: 24969182
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
6. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
[TBL] [Abstract][Full Text] [Related]
7. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
[TBL] [Abstract][Full Text] [Related]
8. Comparing Outcomes between Antibody Induction Therapies in Kidney Transplantation.
Koyawala N; Silber JH; Rosenbaum PR; Wang W; Hill AS; Reiter JG; Niknam BA; Even-Shoshan O; Bloom RD; Sawinski D; Nazarian S; Trofe-Clark J; Lim MA; Schold JD; Reese PP
J Am Soc Nephrol; 2017 Jul; 28(7):2188-2200. PubMed ID: 28320767
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
; Haynes R; Harden P; Judge P; Blackwell L; Emberson J; Landray MJ; Baigent C; Friend PJ
Lancet; 2014 Nov; 384(9955):1684-90. PubMed ID: 25078310
[TBL] [Abstract][Full Text] [Related]
10. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.
Mattei MF; Redonnet M; Gandjbakhch I; Bandini AM; Billes A; Epailly E; Guillemain R; Lelong B; Pol A; Treilhaud M; Vermes E; Dorent R; Lemay D; Blanc AS; Boissonnat P
J Heart Lung Transplant; 2007 Jul; 26(7):693-9. PubMed ID: 17613399
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis.
Hao WJ; Zong HT; Cui YS; Zhang Y
Transplant Proc; 2012 Dec; 44(10):2955-60. PubMed ID: 23195005
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath).
Myers GD; Krance RA; Weiss H; Kuehnle I; Demmler G; Heslop HE; Bollard CM
Bone Marrow Transplant; 2005 Dec; 36(11):1001-8. PubMed ID: 16184180
[TBL] [Abstract][Full Text] [Related]
14. Fungal infections in transplant recipients receiving alemtuzumab.
Nath DS; Kandaswamy R; Gruessner R; Sutherland DE; Dunn DL; Humar A
Transplant Proc; 2005 Mar; 37(2):934-6. PubMed ID: 15848579
[TBL] [Abstract][Full Text] [Related]
15. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
Saull HE; Enderby CY; Gonwa TA; Wadei HM
Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849
[TBL] [Abstract][Full Text] [Related]
16. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim SH; Kim HJ; Cho SG; Eom KS; Lee JW; Min WS; Shin WS; Kim CC
Transpl Infect Dis; 2009 Oct; 11(5):413-23. PubMed ID: 19708893
[TBL] [Abstract][Full Text] [Related]
17. Induction therapy of basiliximab versus antithymocyte globulin in renal allograft: a systematic review and meta-analysis.
Wang K; Xu X; Fan M
Clin Exp Nephrol; 2018 Jun; 22(3):684-693. PubMed ID: 28986715
[TBL] [Abstract][Full Text] [Related]
18. Does Induction Type Influence Outcomes in Kidney Transplant Recipients at Different Phases of Hepatitis B Infection?
Sureshkumar KK; Chopra B
Exp Clin Transplant; 2019 Aug; 17(4):457-460. PubMed ID: 30066624
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA
Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178
[TBL] [Abstract][Full Text] [Related]
20. A comparison of three induction therapies on patients with delayed graft function after kidney transplantation.
Umber A; Killackey M; Paramesh A; Liu Y; Qin H; Atiq M; Lee B; Alper AB; Simon E; Buell J; Zhang R
J Nephrol; 2017 Apr; 30(2):289-295. PubMed ID: 27062485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]